Thrivent Financial for Lutherans significantly reduced its position in Quest Diagnostics (DGX) during the third quarter of 2025, slashing its holdings by 58.3%. The institutional sell-off involved the disposal of 14,080 shares, coinciding with a period of net selling by company insiders, including CEO J. E. Davis. Despite these divestments, Quest Diagnostics recently reported robust fourth-quarter financial results that exceeded expectations. The company also announced a massive $1.0 billion share buyback program and a 7.5% increase in its quarterly dividend to reward shareholders. However, market sentiment remains tempered as the company's 2026 earnings per share guidance fell short of some analyst projections. Investors are now weighing the positive capital return initiatives against the backdrop of institutional and insider exits.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis